Effectiveness of intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) in Ghana

Simple item page
dc.contributor.authorDosoo, D.K.
dc.contributor.authorMalm, K.
dc.contributor.authorOppong, F.B.
dc.contributor.authorGyasi, R.
dc.contributor.authorOduro, A.
dc.contributor.authorWilliams, J.
dc.contributor.authorAtibilla, D.
dc.contributor.authorPeprah, N.Y.
dc.contributor.authorTwumasi, M.
dc.contributor.authorOwusu-Agyei, S.
dc.contributor.authorGreenwood, B.
dc.contributor.authorChandramohan, D.
dc.contributor.authorAsante, K.P.
dc.date.accessioned2021-11-15T11:23:07Z
dc.date.available2021-11-15T11:23:07Z
dc.date.issued2021
dc.descriptionResearch Articleen_US
dc.description.abstractIntroduction Ghana adopted the revised WHO recommendation on intermittent preventive treatment in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) in 2012. This study has assessed the effectiveness and safety of this policy in Ghana. Methods A total of 1926 pregnant women enrolled at antenatal care (ANC) clinics were assessed for birth outcomes at delivery, and placental histology results for malaria infection were obtained from 1642 participants. Association of reduced placental or peripheral malaria, anaemia and low birth weight (LBW) in women who received ≥4 IPTp-SP doses compared with 3 or ≤2 doses was determined by logistic regression analysis. Results Among the 1926 participants, 5.3% (103), 19.2% (369), 33.2% (640) and 42.3% (817) of women had received ≤1, 2, 3 or ≥4 doses, respectively. There was no difference in risk of active placental malaria (PM) infection in women who received 3 doses compared with ≥4 doses (adjusted OR (aOR) 1.00, 95% CI 0.47 to 2.14). The risk of overall PM infection was 1.63 (95% CI 1.07 to 2.48) in 2 dose group and 1.06 (95% CI 0.72 to 1.57) in 3 dose group compared with ≥4 dose group. The risk of LBW was 1.55 (95% CI 0.97 to 2.47) and 1.06 (95% CI 0.68 to 1.65) for 2 and 3 dose groups, respectively, compared with the ≥4 dose group. Jaundice in babies was present in 0.16%, and 0% for women who received ≥4 doses of SP. Conclusion There was no difference in the risk of PM, LBW or maternal anaemia among women receiving 3 doses compared with ≥4 doses. Receiving ≥3 IPTp-SP doses during pregnancy was associated with a lower risk of overall PM infection compared with 2 doses. As there are no safety concerns, monthly administration of IPTp-SP offers a more practical opportunity for pregnant women to receive ≥3 doses during pregnancy.en_US
dc.identifier.othere005877. doi:10.1136/ bmjgh-2021-005877
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/37105
dc.language.isoenen_US
dc.publisherBMJ GLOBAL HEALTHen_US
dc.subjectGhanaen_US
dc.subjectpregnancyen_US
dc.subjectsulphadoxine-pyrimethamineen_US
dc.subjectWHOen_US
dc.subjectpreventive treatmenten_US
dc.titleEffectiveness of intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) in Ghanaen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Effectiveness of intermittent preventive.pdf
Size:
350.23 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Department of Pathology